Making sense of GLP-1 agonists
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
The work of a consultant pharmacist in diabetes spans clinical duties and leadership tasks including education and mentoring. There are at present only three consultant pharmacists in diabetes… read more.
A new Dartmouth study in the journal Science Advances suggests that how well people with diabetes manage their blood sugar depends on their experience with the condition and their overall success… read more.
In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications,… read more.
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.
One promising approach to treating Type 1 diabetes is implanting pancreatic islet cells that can produce insulin when needed, which can free patients from giving themselves frequent insulin… read more.
Persons with an evening ‘chronotype”’ (going to bed late and waking up late), have a 19 percent increased risk of diabetes compared to those with a morning chronotype,… read more.
A simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease, according to new research published today in… read more.
People with type-II diabetes who drank the fermented tea drink kombucha for four weeks had lower fasting blood glucose levels compared to when they consumed a similar-tasting placebo… read more.
You might not think of diabetes when you think of muscle function. But a common diabetes drug that regulates blood sugar can also prevent muscle atrophy and muscular… read more.
Researchers report that patients have achieved significantly better glycemic control with once-weekly investigative insulin icodec than with with once-daily insulin glargine U100. The findings were reported on July… read more.
Renalytix plc announces that the FDA has granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing… read more.
Advertisment